Abstract
Pancreatic enzyme replacement therapy (PERT) is essential for patients with pancreatic exocrine insufficiency. In children, the most common cause of pancreatic insufficiency is cystic fibrosis (CF) followed by Shwachman-Diamond syndrome (SDS) and chronic pancreatitis (CP). When caring for patients with these diagnoses, the first question we ask is whether they have pancreatic insufficiency. Of patients with CF, 10% to 15% will not have pancreatic insufficiency. Larger fractions of patients with SDS or CP will also not have pancreatic insufficiency. Although it is clear that patients with pancreatic insufficiency should be treated with PERT, there is controversy about treating patients with evidence of pancreatic disease who do not have pancreatic insufficiency even though their pancreatic function may be decreased. We generally do not prescribe PERT to patients without objective evidence of pancreatic insufficiency.
Original language | English |
---|---|
Title of host publication | Curbside Consultation in Pediatric GI |
Subtitle of host publication | 49 Clinical Questions |
Publisher | CRC Press |
Pages | 139-142 |
Number of pages | 4 |
ISBN (Electronic) | 9781040143759 |
ISBN (Print) | 9781617110146 |
DOIs | |
State | Published - Jan 1 2024 |